We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Eagle Pharmaceuticals Inc
2 own
12 watching
Current Price
$15.7
$0.47
(3.09%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
246.77M
52-Week High
40.85000
52-Week Low
15.04000
Average Volume
0.07M
Dividend Yield
--
P/E Ratio
37.5328
Market Capitalization246.77M52-Week High40.8500052-Week Low15.04000Average Volume0.07MDividend Yield--P/E Ratio37.5328What does the Eagle Pharmaceuticals Inc do?
Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates includes include EP-4104, a dantrolene sodium for exertional heat stroke; EGL-4104-C-1702, dantrolene sodium for drug induced hyperthermia; EP-5101 (pemetrexed) for lung cancer and mesothelioma; and EGL-5385-C-1701 (fulvestrant) for breast cancer. Eagle Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Read More
How much money does Eagle Pharmaceuticals Inc make?
News & Events about Eagle Pharmaceuticals Inc.
Globe Newswire
6 months ago
WOODCLIFF LAKE, N.J., March 03, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Eagle or the Company) (Nasdaq: EGRX) today announced that the Company will release its fourth quarter and full year 2022 financial results on Monday, March 13, 2023, before the market opens.Scott Tarriff, President...
Globe Newswire
1 year ago
WOODCLIFF LAKE, N.J., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (Eagle or the Company) today announced that the U.S. Court of Appeals for the Federal Circuit affirmed the U.S. District Court for the District of Delawares decision that Eagles vasopressin product ...
Ticker Report
1 year ago
BNP Paribas Arbitrage SA lessened its position in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX Get Rating) by 45.8% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 6,397 shares of the specialty pharmaceutical companys stock after selling 5,396 ...
Ticker Report
1 year ago
Principal Financial Group Inc. decreased its position in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX Get Rating) by 10.9% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 87,897 shares of the specialty pharmaceutical company&#...
Ticker Report
1 year ago
Equities analysts forecast that Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX Get Rating) will report earnings per share of $3.91 for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Eagle Pharmaceuticals earnings, with estimates ...
Frequently Asked Questions
Frequently Asked Questions
What is Eagle Pharmaceuticals Inc share price today?
Can Indians buy Eagle Pharmaceuticals Inc shares?
How can I buy Eagle Pharmaceuticals Inc shares from India?
Can Fractional shares of Eagle Pharmaceuticals Inc be purchased?
What are the documents required to start investing in Eagle Pharmaceuticals Inc stocks?
What is today’s traded volume of Eagle Pharmaceuticals Inc?
What is today’s market capitalisation of Eagle Pharmaceuticals Inc?
What is the 52-Week High and Low Range of Eagle Pharmaceuticals Inc?
What percentage is Eagle Pharmaceuticals Inc down from its 52-Week High?
What percentage is Eagle Pharmaceuticals Inc up from its 52-Week Low?
Current Price
$15.7
$0.47
(3.09%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.